Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

18.040
-0.430-2.33%
Volume:415.09K
Turnover:7.44M
Market Cap:47.77B
PE:12.14
High:18.650
Open:18.650
Low:17.680
Close:18.470
52wk High:26.110
52wk Low:14.505
Shares:2.65B
HK Float Shares:530.00M
Volume Ratio:0.31
T/O Rate:0.08%
Dividend:0.46
Dividend Rate:2.53%
EPS(LYR):1.486
ROE:6.95%
ROA:1.40%
PB:0.84
PE(LYR):12.14
PS:0.96

Loading ...

Sinopharm Group Stock Rallies 1.1% in Hong Kong

Dow Jones
·
Aug 26

Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents

Deep News
·
Aug 26

Fosun Pharma Posts Flat Profit Growth in H1, Revenue Up 4.8%

MT Newswires Live
·
Aug 26

Press Release: Fosun Pharma Announces 2026 Interim Results

Dow Jones
·
Aug 25

Sinopharm Group Stock Falls 1.9% in Hong Kong

Dow Jones
·
Aug 24

Earning Preview: FOSUN PHARMA this quarter’s revenue is expected to increase by 8.56%, and institutional views are broadly bullish

Earnings Agent
·
Aug 18

Fosun Pharma Subsidiary Enters Collaboration Framework and License Agreement

Stock News
·
Aug 17

Shanghai Fosun's Unit in Collaboration with Sandoz AG on 10 Biologic Products

Reuters
·
Aug 17

Shanghai Fosun Pharmaceutical Says to Team up Sandoz on Commercialization, Development, Manufacturing of up to 10 Biologic Products

THOMSON REUTERS
·
Aug 17

Shanghai Fosun Pharmaceutical Says Unit Signs Framework Cooperation Agreement with Sandoz Ag

THOMSON REUTERS
·
Aug 17

FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD

Bulletin Express
·
Aug 13

Fosun Pharma Schedules 25 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 13

Sinopharm Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Aug 11

Fosun Pharma Secures China Approval for Two Drugs

MT Newswires Live
·
Aug 10

Fosun Pharma Subsidiary Secures NMPA Approval for Dobutamine Hydrochloride Injection

Bulletin Express
·
Aug 07

Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution

Bulletin Express
·
Aug 07

Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug

Deep News
·
Aug 07

Fosun Pharma's Dobutamine Hydrochloride Injection Receives NMPA Marketing Approval

Stock News
·
Aug 07

Shanghai Fosun Pharma - Drug Registration Application for Dobutamine Hydrochloride Injection Approved by Nmpa

THOMSON REUTERS
·
Aug 07

Sinopharm Group Stock Sheds 0.8% in Hong Kong

Dow Jones
·
Aug 07